AKRO Stock Overview
Together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Akero Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.73 |
| 52 Week High | US$37.00 |
| 52 Week Low | US$15.32 |
| Beta | -0.26 |
| 11 Month Change | 11.59% |
| 3 Month Change | 19.71% |
| 1 Year Change | 100.31% |
| 33 Year Change | 54.90% |
| 5 Year Change | 66.23% |
| Change since IPO | 78.66% |
Recent News & Updates
Recent updates
Akero Therapeutics: Good Candidate For The MASH Basket
Sep 20Akero Therapeutics' EFX Data Warrants Caution
Apr 03Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program
Mar 04Akero Therapeutics announces closing of upsized public offering
Sep 19Akero adds over 100% rallying peers after NASH success
Sep 13We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate
May 04
We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth
Jan 15Shareholder Returns
| AKRO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 16.5% | 2.5% | 2.2% |
| 1Y | 100.3% | 16.1% | 31.6% |
Return vs Industry: AKRO exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: AKRO exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| AKRO volatility | |
|---|---|
| AKRO Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AKRO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AKRO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 60 | Andrew Cheng | akerotx.com |
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.
Akero Therapeutics, Inc. Fundamentals Summary
| AKRO fundamental statistics | |
|---|---|
| Market cap | US$2.28b |
| Earnings (TTM) | -US$237.22m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.6x
P/E RatioIs AKRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKRO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$237.22m |
| Earnings | -US$237.22m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.8% |
How did AKRO perform over the long term?
See historical performance and comparison